[8-K] Healthcare Triangle, Inc. Reports Material Event

Rhea-AI Filing Summary

Sage Therapeutics, Inc. (SAGE) filed a Post-Effective Amendment to 15 previously effective Form S-8 registrations to deregister all remaining, unissued shares that had been reserved for employee equity plans. The action follows the 31 Jul 2025 closing of the merger whereby Supernus Pharmaceuticals, Inc. acquired Sage through its subsidiary Saphire, Inc., leaving Sage a wholly owned subsidiary of Supernus.

The affected registrations covered roughly 35 million shares across the 2011 Stock Option & Grant Plan, the 2014 Stock Option & Incentive Plan, multiple ESPPs, the 2016 and 2024 inducement/equity incentive plans, and related amendments. Because Sage’s securities offerings have ceased, the company is fulfilling its undertaking under Rule 415 to remove from registration any securities that remain unsold at termination of the offering. No additional securities will be issued under the listed plans, and the filings are amended solely to reflect this deregistration.

Insights

Corporate Actions Analyst

TL;DR: Housekeeping filing; all unused S-8 shares removed after Supernus acquisition—neutral to investors.

The amendment is a routine step completed after the 31 July 2025 merger closed. Once Sage became a wholly owned subsidiary of Supernus, its public equity programs ceased to exist. Consequently, the company must legally deregister any shares that will never be issued. This does not alter deal economics already set in the merger agreement and has no incremental cash impact on Supernus or former Sage shareholders. It simply cleans the SEC register and eliminates future share-based issuance capacity at the Sage level. Overall impact on valuation, liquidity, or capital structure is negligible.

false --12-31 0001839285 0001839285 2025-07-30 2025-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 30, 2025

HEALTHCARE TRIANGLE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40903		84-3559776
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7901 Stoneridge Dr., Suite 220 Pleasanton, CA 94588

(Address of principal executive offices)

(925)-270-4812

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		HCTI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03. Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

To the extent required by Item 5.03 of Form 8-K, the information contained in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01. Other Events

On August 1, 2025, Healthcare Triangle, Inc. (the “Company”) effected a one-for-two hundred forty-nine (1:249) reverse stock split of all issued and outstanding shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) effective as of 12:01 a.m. Eastern Time on August 1, 2025 (the “Reverse Stock Split”), vide  a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Healthcare Triangle, Inc (the “Certificate of Amendment”) filed with the Secretary of State of Delaware, and deemed effective on August 1, 2025 at 12:01 a.m. Eastern Time. The Reverse Stock Split was intended to bring the Company into compliance with the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market, as required by Nasdaq Listing Rule 5550(a)(2).

As a result of the Reverse Stock Split, every two hundred forty-nine (249) shares of issued and outstanding Common Stock combined into one (1) validly issued, fully paid and nonassessable share of Common Stock. The Reverse Stock Split uniformly affected all issued and outstanding shares of Common Stock and did not alter any stockholder’s percentage ownership interest in the Company, except to the extent that the Reverse Stock Split resulted in the fractional interests. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock were automatically entitled to receive an additional fraction of a share of common stock to round up to the next whole share, at a participant level. Proportional adjustments have also been made to the Company’s outstanding warrants, stock options, and convertible securities, as well as to the reserves available pursuant to the terms of the Company’s 2020 Equity Incentive Plans to reflect the Reverse Stock Split, in each case, in accordance with the terms thereof.

The Reverse Stock Split reduced the number of shares of Common Stock issued and outstanding from 1,452,124,283 to 5,831,816 shares of Common Stock. The number of authorized shares of Common Stock did not change by the Reverse Stock Split.

The Company’s transfer agent, VStock Transfer, LLC acted as the exchange agent for the reverse stock split. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.

The Common Stock started trading on a split-adjusted basis on the NASDAQ Capital Market at the market open on August 1, 2025. The trading symbol for the Common Stock remains “HCTI.” Following the Reverse Stock Split, the CUSIP for the Company’s Common Stock is 42227W 306.

The description of the Certificate of Correction to the Certificate of Amendment, and the Certificate of Amendment is qualified in its entirety by reference to the text of the Certificate of Correction to the Certificate of Amendment, and the Certificate of Amendment, which are filed as Exhibits 3.1, and 3.2 to this Current Report on Form 8-K and are incorporated herein by reference.

1

On July 30, 2025, the Company issued a press release announcing the Reverse Stock Split. The full text of the Company’s press release issued in connection with the foregoing matter is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Amendment to Certificate of Incorporation of Healthcare Triangle, Inc.
3.2		Certificate of Correction to Certificate of Amendment to Certificate of Incorporation of Healthcare Triangle, Inc.
99.1		Press Release, dated as of July 30, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

Forward-Looking Statements

Certain statements made in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Current Report on Form 8-K are forward-looking statements. When used in this Current Report on Form 8-K, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of these words or similar expressions (or the negative versions of such words or expressions), as they relate to the Company or its management team, are intended to identify forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K, including the Company’s ability to successfully appeal the Nasdaq staff’s delisting determination and the Company’s ability to have an application to trade on the OTCQB approved timely to commence trading if its common shares are delisted from Nasdaq. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 31, 2025, and other reports and registration statements of the Company filed, or to be filed, with the Securities and Exchange Commission, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. The Company undertakes no obligation to update or revise any forward-looking statements for revisions or changes after the date of this Current Report on Form 8-K, except as required by law.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Healthcare Triangle, Inc.
Dated: August 1, 2025	By:	/s/ David Ayanoglou
		David Ayanoglou
		Chief Financial Officer

3

FAQ

Why did Sage Therapeutics file this S-8 POS amendment?

To deregister all shares that were reserved under its equity plans but remain unissued after the 31 Jul 2025 merger with Supernus.

How many shares are being deregistered by SAGE?

Approximately 35 million common shares across 15 separate S-8 registration statements.

What happened to Sage Therapeutics on 31 July 2025?

It merged with a Supernus Pharmaceuticals subsidiary and now operates as a wholly owned subsidiary of Supernus.

Will Sage issue any more shares under its employee equity plans?

No. All listed plans are terminated, and no additional shares will be issued.

Does this filing affect Supernus (SUPN) shareholders?

The amendment is administrative and has no direct financial impact on Supernus; merger terms remain unchanged.